Astellas Pharma Inc. has divulged substituted quinolone derivates acting as acetylcholine receptor cluster inducers reported to be useful for the treatment of neuromuscular disorders.
Shanghai Haiyan Pharmaceutical Technology Co. Ltd. and Yangtze River Pharmaceutical Group have synthesized macrophage colony-stimulating factor 1 receptor (CSF-1R; CD115; c-Fms) inhibitors reported to be useful for the treatment of cancer.
Researchers at Association Française Contre Les Myopathies, Consiglio Nazionale delle Ricerche, and Università degli Studi di Roma La Sapienza have disclosed peptidomimetics derived from leucyl-tRNA synthetase.
Researchers at Shanghai Jingxin Biomedical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have described fused bicyclic heteroaryl amide compounds acting as α-synuclein (SNCA) aggregation inhibitors reported to be useful for the treatment of frontotemporal, Lewy body and Parkinson's dementia, multiple system atrophy, and more.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase coupled to Wee1-like protein kinase (Wee1) targeting moiety via linker acting as Wee1 degradation inducers reported to be useful for the treatment of cancer.
Suzhou Ark Biopharmaceutical Co. Ltd. has synthesized 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Lynk Pharmaceuticals Co. Ltd. has disclosed nitrogen-containing heterocyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Shanghai Euregen Biopharma Co. Ltd. has described pyridazine compounds acting as son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12C mutant) interaction inhibitors reported to be useful for the treatment of cancer.
RSS